Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
32
PBIO Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
56.24%
Day range:
$0.0007 - $0.0407
52-week range:
$0.0001 - $0.2000
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.02x
P/B ratio:
--
Volume:
14.9K
Avg. volume:
6.6K
1-year change:
-80%
Market cap:
$28.7K
Revenue:
$2M
EPS (TTM):
-$1.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PBIO
Pressure BioSciences, Inc.
|
-- | -- | -- | -- | -- |
|
ABMT
Advanced BioMedical Technologies, Inc.
|
-- | -- | -- | -- | -- |
|
CATX
Perspective Therapeutics, Inc.
|
$147K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
INND
Innerscope Hearing Technologies
|
-- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$806.3K | -$0.04 | 272.5% | -33.67% | $2.20 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$28.5M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PBIO
Pressure BioSciences, Inc.
|
$0.0007 | -- | $28.7K | -- | $0.00 | 0% | 0.02x |
|
ABMT
Advanced BioMedical Technologies, Inc.
|
$0.0004 | -- | $28.1K | -- | $0.00 | 0% | 0.07x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8800 | $12.3077 | $214.1M | -- | $0.00 | 0% | 195.28x |
|
INND
Innerscope Hearing Technologies
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
VNRX
VolitionRX Ltd.
|
$0.25 | $2.20 | $30.7M | -- | $0.00 | 0% | 17.13x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.78 | $1.50 | $108.6M | 76.08x | $0.00 | 0% | 0.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PBIO
Pressure BioSciences, Inc.
|
-228.31% | 3.907 | 321.48% | 0.00x |
|
ABMT
Advanced BioMedical Technologies, Inc.
|
-- | 0.754 | -- | -- |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
INND
Innerscope Hearing Technologies
|
-- | 0.000 | -- | -- |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.566 | 15.4% | 0.04x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PBIO
Pressure BioSciences, Inc.
|
$116K | -$1.5M | -- | -- | -770.04% | -$1.9M |
|
ABMT
Advanced BioMedical Technologies, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
INND
Innerscope Hearing Technologies
|
-- | -- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Pressure BioSciences, Inc. vs. Competitors
-
Which has Higher Returns PBIO or ABMT?
Advanced BioMedical Technologies, Inc. has a net margin of -2311.89% compared to Pressure BioSciences, Inc.'s net margin of --. Pressure BioSciences, Inc.'s return on equity of -- beat Advanced BioMedical Technologies, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBIOPressure BioSciences, Inc.33.2% -$0.22 -$11.6M ABMTAdvanced BioMedical Technologies, Inc.-- -- -- -
What do Analysts Say About PBIO or ABMT?
Pressure BioSciences, Inc. has a consensus price target of --, signalling upside risk potential of 634185.71%. On the other hand Advanced BioMedical Technologies, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Pressure BioSciences, Inc. has higher upside potential than Advanced BioMedical Technologies, Inc., analysts believe Pressure BioSciences, Inc. is more attractive than Advanced BioMedical Technologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBIOPressure BioSciences, Inc.0 0 0 ABMTAdvanced BioMedical Technologies, Inc.0 0 0 -
Is PBIO or ABMT More Risky?
Pressure BioSciences, Inc. has a beta of -0.126, which suggesting that the stock is 112.59% less volatile than S&P 500. In comparison Advanced BioMedical Technologies, Inc. has a beta of 1.428, suggesting its more volatile than the S&P 500 by 42.833%.
-
Which is a Better Dividend Stock PBIO or ABMT?
Pressure BioSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Advanced BioMedical Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pressure BioSciences, Inc. pays -- of its earnings as a dividend. Advanced BioMedical Technologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBIO or ABMT?
Pressure BioSciences, Inc. quarterly revenues are $349.3K, which are larger than Advanced BioMedical Technologies, Inc. quarterly revenues of --. Pressure BioSciences, Inc.'s net income of -$8.1M is higher than Advanced BioMedical Technologies, Inc.'s net income of --. Notably, Pressure BioSciences, Inc.'s price-to-earnings ratio is -- while Advanced BioMedical Technologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pressure BioSciences, Inc. is 0.02x versus 0.07x for Advanced BioMedical Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBIOPressure BioSciences, Inc.0.02x -- $349.3K -$8.1M ABMTAdvanced BioMedical Technologies, Inc.0.07x -- -- --
-
Which has Higher Returns PBIO or CATX?
Perspective Therapeutics, Inc. has a net margin of -2311.89% compared to Pressure BioSciences, Inc.'s net margin of -12425.36%. Pressure BioSciences, Inc.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital PBIOPressure BioSciences, Inc.33.2% -$0.22 -$11.6M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About PBIO or CATX?
Pressure BioSciences, Inc. has a consensus price target of --, signalling upside risk potential of 634185.71%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 327.35%. Given that Pressure BioSciences, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Pressure BioSciences, Inc. is more attractive than Perspective Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBIOPressure BioSciences, Inc.0 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is PBIO or CATX More Risky?
Pressure BioSciences, Inc. has a beta of -0.126, which suggesting that the stock is 112.59% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock PBIO or CATX?
Pressure BioSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pressure BioSciences, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBIO or CATX?
Pressure BioSciences, Inc. quarterly revenues are $349.3K, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Pressure BioSciences, Inc.'s net income of -$8.1M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Pressure BioSciences, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pressure BioSciences, Inc. is 0.02x versus 195.28x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBIOPressure BioSciences, Inc.0.02x -- $349.3K -$8.1M CATXPerspective Therapeutics, Inc.195.28x -- $209K -$26M
-
Which has Higher Returns PBIO or INND?
Innerscope Hearing Technologies has a net margin of -2311.89% compared to Pressure BioSciences, Inc.'s net margin of --. Pressure BioSciences, Inc.'s return on equity of -- beat Innerscope Hearing Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBIOPressure BioSciences, Inc.33.2% -$0.22 -$11.6M INNDInnerscope Hearing Technologies-- -- -- -
What do Analysts Say About PBIO or INND?
Pressure BioSciences, Inc. has a consensus price target of --, signalling upside risk potential of 634185.71%. On the other hand Innerscope Hearing Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Pressure BioSciences, Inc. has higher upside potential than Innerscope Hearing Technologies, analysts believe Pressure BioSciences, Inc. is more attractive than Innerscope Hearing Technologies.
Company Buy Ratings Hold Ratings Sell Ratings PBIOPressure BioSciences, Inc.0 0 0 INNDInnerscope Hearing Technologies0 0 0 -
Is PBIO or INND More Risky?
Pressure BioSciences, Inc. has a beta of -0.126, which suggesting that the stock is 112.59% less volatile than S&P 500. In comparison Innerscope Hearing Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PBIO or INND?
Pressure BioSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innerscope Hearing Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pressure BioSciences, Inc. pays -- of its earnings as a dividend. Innerscope Hearing Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBIO or INND?
Pressure BioSciences, Inc. quarterly revenues are $349.3K, which are larger than Innerscope Hearing Technologies quarterly revenues of --. Pressure BioSciences, Inc.'s net income of -$8.1M is higher than Innerscope Hearing Technologies's net income of --. Notably, Pressure BioSciences, Inc.'s price-to-earnings ratio is -- while Innerscope Hearing Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pressure BioSciences, Inc. is 0.02x versus -- for Innerscope Hearing Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBIOPressure BioSciences, Inc.0.02x -- $349.3K -$8.1M INNDInnerscope Hearing Technologies-- -- -- --
-
Which has Higher Returns PBIO or VNRX?
VolitionRX Ltd. has a net margin of -2311.89% compared to Pressure BioSciences, Inc.'s net margin of -862.39%. Pressure BioSciences, Inc.'s return on equity of -- beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBIOPressure BioSciences, Inc.33.2% -$0.22 -$11.6M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About PBIO or VNRX?
Pressure BioSciences, Inc. has a consensus price target of --, signalling upside risk potential of 634185.71%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 780%. Given that Pressure BioSciences, Inc. has higher upside potential than VolitionRX Ltd., analysts believe Pressure BioSciences, Inc. is more attractive than VolitionRX Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PBIOPressure BioSciences, Inc.0 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is PBIO or VNRX More Risky?
Pressure BioSciences, Inc. has a beta of -0.126, which suggesting that the stock is 112.59% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.
-
Which is a Better Dividend Stock PBIO or VNRX?
Pressure BioSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pressure BioSciences, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBIO or VNRX?
Pressure BioSciences, Inc. quarterly revenues are $349.3K, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Pressure BioSciences, Inc.'s net income of -$8.1M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Pressure BioSciences, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pressure BioSciences, Inc. is 0.02x versus 17.13x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBIOPressure BioSciences, Inc.0.02x -- $349.3K -$8.1M VNRXVolitionRX Ltd.17.13x -- $627.3K -$5.4M
-
Which has Higher Returns PBIO or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -2311.89% compared to Pressure BioSciences, Inc.'s net margin of 3.93%. Pressure BioSciences, Inc.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital PBIOPressure BioSciences, Inc.33.2% -$0.22 -$11.6M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About PBIO or XTNT?
Pressure BioSciences, Inc. has a consensus price target of --, signalling upside risk potential of 634185.71%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 93.3%. Given that Pressure BioSciences, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Pressure BioSciences, Inc. is more attractive than Xtant Medical Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBIOPressure BioSciences, Inc.0 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is PBIO or XTNT More Risky?
Pressure BioSciences, Inc. has a beta of -0.126, which suggesting that the stock is 112.59% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock PBIO or XTNT?
Pressure BioSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pressure BioSciences, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBIO or XTNT?
Pressure BioSciences, Inc. quarterly revenues are $349.3K, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Pressure BioSciences, Inc.'s net income of -$8.1M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Pressure BioSciences, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pressure BioSciences, Inc. is 0.02x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBIOPressure BioSciences, Inc.0.02x -- $349.3K -$8.1M XTNTXtant Medical Holdings, Inc.0.85x 76.08x $33.3M $1.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
